Bristol-myers Squibb Compnay

Taimed Biologics, Inc.

Francis Beaulieu

Carl Ouellet

B Narasimhulu Naidu

Yasutsugu Ueda

Michael A Walker

Jacques Banville

John D Matiskella

Edward H Ruediger

Carol Bachand

Timothy P Connolly

Margaret E Sorenson

Roger Remillard

Serge Plamondon

Mark D Wittman

Kurt Zimmermann

Neelakantan Balasubramanian

Mark R Krystal

Mikael Mahler

Makonen Belema

Mark George Saulnier

Upender Velaparthi

Anne Marinier

David Bertil Frennesson

Yuping Qiu

Stephan Roy

Chen Li

Xuejie Yang

Nicholas A Meanwell

Annapurna Pendri

Alain Martel

Denis R St Laurent

Van N Nguyen

Manoj Patel

Katharine A Grant-Young

Kevin M Peese

Brent Richard Stranix

Yunhui Zhang

Fred Christopher Zusi

Amy Mae Bunker

Guy Milot

Jean-Emmanuel Bouchard

Karen M Stoffan

Ting T Yin

Wang Zhigang

Jonathan R Weiss

Carl Quellet

Christopher Zusi

Neelakantan Balusubramanian

Byron Hepler Long

Réjean Ruel

The present invention relates to pyridoxine (vitamin B) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R, R, R, A, L Band Bare as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS. 

HIV integrase inhibitors from pyridoxine

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

Tyrosine kinase inhibitors

Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Benzimidazole C-2 heterocycles as kinase inhibitors

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.

Topoisomerase inhibitors

Compounds of formula (I), or pharmaceutically-acceptable salts thereof, are useful in treating inflammatory and immune diseases and disorders,

Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Compounds having the formula (I),and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R, R, and Rare hydrogen, halogen, alkyl, or perfluoroalkyl; Ris an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and Ris a substituent on A as defined in the specification.

Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same

The present invention relates to fluoro sugar and other sugar derivatives of indolopyrrolocarbazoles, their salts and hydrates, which exhibit selective topoisomerase I (topo I) activity, are useful in inhibiting the proliferation of tumor cells and exhibit an antitumor effect, as well as processes for their preparation.

Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles

The present invention relates to novel N12, N13-bridged sugar derivatives of indolylopyrrolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.

Growing community of inventors

La Prairie, Canada

Francis Beaulieu